Optimal management of metastatic melanoma: Current strategies and future directions

American Journal of Clinical Dermatology

Volumn 14, Issue 3, 2013, Pages 179-194

  Batus, Marta ^a   Waheed, Salman ^a   Ruby, Carl ^a   Petersen, Lindsay ^a   Bines, Steven D ^a   Kaufman, Howard L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIBODY; B RAF KINASE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DABRAFENIB; DACARBAZINE; FIBRONECTIN; FLUDARABINE; GLYCOPROTEIN GP 100; IMATINIB; IMIQUIMOD; INTERLEUKIN 2; IPILIMUMAB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; SELUMETINIB; STEM CELL FACTOR; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VEMURAFENIB; VINBLASTINE;

ACNE; ADOPTIVE TRANSFER; ALOPECIA; ARTHRALGIA; ASTHENIA; BIOCHEMOTHERAPY; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CEREBROVASCULAR ACCIDENT; COLITIS; CYTOKINE PRODUCTION; CYTOPENIA; DERMATITIS; DIARRHEA; DISEASE COURSE; DISEASE FREE INTERVAL; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; FATIGUE; FEVER; FOLLOW UP; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEPATITIS; HUMAN; HYPERKERATOSIS; HYPOTENSION; INJECTION SITE PAIN; KERATOACANTHOMA; LONG TERM SURVIVAL; LUNG EMBOLISM; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MELANOMA; META ANALYSIS (TOPIC); METASTASIS RESECTION; METASTATIC MELANOMA; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYALGIA; NAUSEA; NEURITIS; NEUTROPENIA; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SKIN METASTASIS; STEREOTACTIC RADIOSURGERY; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TACHYCARDIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUMOR MICROENVIRONMENT; VOMITING; WHOLE BODY RADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; FORECASTING; HUMANS; IMMUNOTHERAPY; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS;

EID: 84878762356     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-013-0025-9     Document Type: Review

References (165)

1. Gray-Schopfer V, Wellbrock C, Marias R. Melanoma biology and new targeted therapy. Nature. 2007;445:851-7.
2. Ko JM, Fisher DE. A new era: melanoma genetics and therapeutics. J Pathol. 2011;223:241-50.
3. Eggermont AM. Advances in systemic treatment of melanoma. Ann Oncol. 2010;21(Suppl. 7):viii339-44.
4. Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatments in melanoma: current status and future prospects. Oncologist. 2011;16:5-24.
5. Nathanson KL. Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. Biochem Pharmacol. 2010;80:755-61.
6. Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol. 2005;6(3):185-93.
7. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-206.
8. Wasif N, Bagaria SP, Ray P, et al. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol. 2011;104(2):111-5.
9. Essner R, Lee JH, Wanek LA, et al. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004;139(9):961-6.
10. Lee CC, Faries MB, Wanek LA, et al. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol. 2008;26(4):535-41.
11. Neuman HB, Patel A, Hanlon C, et al. Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol. 2007;14(10):2847-53.
12. Schuhan C, Muley T, Dienemann H, et al. Survival after pulmonary metastasectomy in patients with malignant melanoma. Thorac Cardiovasc Surg. 2011;59(3):158-62.
13. Petersen RP, Hanish SI, Haney JC, et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 2007;133(1):104-10.
14. Conill C, Gimferrer JM, Marruecos J, et al. Clinical outcome after surgical resection of lung metastases from melanoma. Clin Transl Oncol. 2007;9(1):48-52.
15. Andrews S, Robinson L, Cantor A, et al. Survival after surgical resection of isolated pulmonary metastases from malignant melanoma. Cancer Control. 2006;13(3):218-23.
16. Lewis CW Jr, Harpole D. Pulmonary metastasectomy for metastatic malignant melanoma. Semin Thorac Cardiovasc Surg. 2002;14(1):45-8.
17. Yang SC. Pulmonary metastasectomy for melanoma: beyond the standard of care. Ann Surg Oncol. 2007;14(10):2696-7.
18. Liang KV, Sanderson SO, Nowakowski GS, et al. Metastatic malignant melanoma of the gastrointestinal tract. Mayo Clin Proc. 2006;81(4):511-6.
19. Chua TC, Saxena A, Morris DL. Surgical metastasectomy in AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases. Ann Acad Med Singap. 2010;39(8):634-9.
20. Sanki A, Scolyer RA, Thompson JF. Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Eur J Surg Oncol. 2009;35(3):313-9.
21. Baars A, van Riel JM, Cuesta MA, et al. Metastasectomy and active specific immunotherapy for a large single melanoma metastasis. Hepatogastroenterology. 2002;49(45):691-3.
22. Woon WW, Haghighi KS, Zuckerman RS, et al. Liver resection and cryotherapy for metastatic melanoma. Int Surg. 2008;93(5):274-7.
23. Pawlik TM, Zorzi D, Abdalla EK, et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol. 2006;13(5):712-20.
24. Mittendorf EA, Lim SJ, Schacherer CW, et al. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg. 2008;195(3):363-8.
25. Sturgeon C, Leong SP, Duh QY. Laparoscopic surgery for melanoma metastases to the adrenal gland. Expert Rev Anticancer Ther. 2004;4(5):837-41.
26. Zacest AC, Basser M, Stevens G, et al. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J Neurosurg. 2002;96(3):552-8.
27. Carrubba CJ, Vitaz TW. Factors affecting the outcome after treatment for metastatic melanoma to the brain. Surg Neurol. 2009;72(6):707-11.
28. Majer M, Samlowski WE. Management of metastatic melanoma patients with brain metastases. Curr Oncol Rep. 2007;9(5):4111-6.
29. Douglas JG, Margolin K. The treatment of brain metastases from malignant melanoma. Semin Oncol. 2002;29(5):518-24.
30. Lonser RR, Song DK, Klapper J, et al. Surgical management of melanoma brain metastases in patients treated with immunotherapy. J Neurosurg. 2011;115(1):30-6.
31. Ollila DW, Gleisner AL, Hsueh EC. Rationale for complete metastasectomy in patients with stage IV metastatic melanoma. J Surg Oncol. 2011;104(4):420-4.
32. Morton DL. Melanoma: are we there yet? J Surg Oncol. 2011;104(4):337.
33. Faries MB, Ariyan S. Current surgical treatment in melanoma. Curr Probl Cancer. 2011;35(4):173-84.
34. Sosman JA, Moon J, Tuthill RJ, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011;117(20):4740-6.
35. Caudle AS, Ross MI. Metastasectomy for stage IV melanoma: for whom and how much? Surg Oncol Clin N Am. 2011;20(1):133-44.
36. Hussussian CJ. Surgical treatment of advanced melanoma. Clin Plast Surg. 2010;37(1):161-8.
37. Wargo JA, Tanabe K. Surgical management of melanoma. Hematol Oncol Clin N Am. 2009;23(3):565-81.
38. Smylie M, Claveau J, Alanen K, et al. Management of malignant melanoma: best practices. J Cutan Med Surg. 2009;13(2):55-73.
39. Mosca PJ, Teicher E, Nair SP, et al. Can surgeons improve survival in stage IV melanoma? J Surg Oncol. 2008;97(5):462-8.
40. Young SE, Martinez SR, Essner R. The role of surgery in treatment of stage IV melanoma. J Surg Oncol. 2006;94(4):344-51.
41. Faries MB, Morton DL. The promise of metastasectomy in melanoma. Ann Surg Oncol. 2006;13(5):607-9.
42. Ollila DW, Caudle AS. Surgical management of distant metastases. Surg Oncol Clin N Am. 2006;15(2):385-98.
43. Wong SL, Coit DG. Role of surgery in patients with stage IV melanoma. Curr Opin Oncol. 2004;16(2):155-60.
44. Essner R. Surgical treatment of malignant melanoma. Surg Clin N Am. 2003;83(1):109-56.
45. Allen PJ, Coit DG. The surgical management of metastatic melanoma. Ann Surg Oncol. 2002;9(8):762-70.
46. Allen PJ, Coit DG. The role of surgery for patients with metastatic melanoma. Curr Opin Oncol. 2002;14(2):221-6.
47. Komorowski AL, Wysocki WM, White RL Jr. Surgical management of solitary metastatic melanoma. Acta Chir Belg. 2009;109(2):155-8.
48. Martinez SR, Young SE. A rational surgical approach to the treatment of distant melanoma metastases. Cancer Treat Rev. 2008;34(7):614-20.
49. Tauceri F, Mura G, Roseano M, et al. Surgery and adjuvant therapies in the treatment of stage IV melanoma: our experience in 84 patients. Langenbecks Arch Surg. 2009;394(6):1079-84.
50. Tomov T, Siegel R, Bembenek A. Long-term survival in stage IV melanoma after repetitive surgical therapy. Onkologie. 2008;31(5):259-61.
51. Spanknebel K, Kaufman HL. Surgical treatment of stage IV melanoma. Clin Dermatol. 2004;22(3):240-50.
52. Tagawa ST, Cheung E, Banta W, et al. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer. 2006;106(6):1353-7.
53. Lotem M, Peretz T, Drize O, et al. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV): the new American Joint Committee on Cancer. Br J Cancer. 2002;86(10):1534-9.
54. Guba M, Steinbauer M, Ruhland V, et al. Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma. Oncol Rep. 2002;9(5):981-4.
55. Lens M. Current clinical overview of cutaneous melanoma. Br J Nurs. 2008;17(5):300-5.
56. Kim C, Lee CW, Kovacic L, et al. Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. Oncologist. 2010;15:765-71.
57. Middleton MR, Grob JJ, Aronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. J Clin Oncol. 2000;18:158-66.
58. Bajetta E, Del Vecchio M, Nova P, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma. Ann Oncol. 2006;17:571-7.
59. O'Day SJ, Kim CJ, Reintgen DS. Metastatic melanoma: chemotherapy to biochemotherapy. Cancer Control. 2002;9(1):31-8.
60. Pflugfelder A, Eigentler TK, Keim U, et al. Effectiveness of carboplatin and paclitaxel as first- and second-line treatment of 61 patients with metastatic melanoma. PLoS One. 2011;6(2):e16882.
61. Chapman PB, Panageas KS, Williams L, et al. Clinical results using biochemotherapy as a standard of care in advanced melanoma. Melanoma Res. 2002;12:381-7.
62. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alpha-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26:5748-54.
63. Ives NJ, Stowe RL, Lorigan P, et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2621 patients. J Clin Oncol. 2007;25:5426-34.
64. Atkins MB, Gollob JA, Sosman JA, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-α2B in patients with metastatic melanoma. Clin Cancer Res. 2002;8:3075-81.
65. ®) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol. 2007;6:759-66.
66. Gradishar WJ, Tjulandin S, Davidson N, et al. Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: results of a phase III trial. J Clin Oncol. 2005;23:7794-803.
67. Hersh EM, O'Day SJ, Ribas A, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naïve patients with metastatic melanoma. Cancer. 2010;116:155-63.
68. Kottschade LA, Suman VJ, Amatruda T III, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma. Cancer. 2011;117:1704-10.
69. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-70.
70. Krieg C, Létourneau S, Pantaleo G, et al. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci USA. 2010;107(26):11906-11.
71. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-16.
72. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6(Suppl. 1):S11-4.
73. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park). 2009;23(6):488-96.
74. Sosman JA, Carillo C, Urba WJ, et al. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol. 2008;26(14):2292-8.
75. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4(3):321-7.
76. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119-27.
77. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270(5238):985- 8.
78. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541-7.
79. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity. 1997;7(6):885-95.
80. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-48.
81. Salama AK, Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res. 2011;17(14):4622-8.
82. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190(3):355-66.
83. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155-64.
84. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010;21(8):1712-7.
85. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15(17):5591-8.
86. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
87. Robinson MR, Chan CC, Yang JC, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004;27(6):478-9.
88. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28(6):593-8.
89. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100(14):8372-7.
90. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027-34.
91. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682-7.
92. Hirano F, Kameko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089-96.
93. Sheppard KA, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004;574(1-3):37-41.
94. Okazaki T, Maeda A, Nishimura H, et al. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA. 2001;98(24):13866-71.
95. Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169(10):5538-45.
96. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99(19):12293-7.
97. Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116(7):1757-66.
98. He YF, Zhang GM, Wang XH, et al. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol. 2004;173(8):4919-28.
99. Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63(19):6501-5.
100. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813-24.
101. Brahmer JR, Drake CJ, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167-75.
102. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54.
103. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65.
104. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 2010;107(9):4275-80.
105. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233-9.
106. Besser MJ, Shapira-Frommer R, Treves AJ, et al. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J Immunother. 2009;32(4):415-23.
107. Muranski P, Boni A, Wrzesinski C, et al. Increased intensity lymphodepletion and adoptive immunotherapy: how far can we go? Nat Clin Pract Oncol. 2006;3(12):668-81.
108. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346-57.
109. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850-4.
110. Murphy A, Westwood JA, Teng MW, et al. Gene modification strategies to induce tumor immunity. Immunity. 2005;22(4):403-14.
111. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3(1):35-45.
112. Johnson LA, Morga RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535-46.
113. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-9.
114. Han Y, Guo Q, Zhang M, et al. CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol. 2009;182(1):111-20.
115. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity. 2009;30(5):626-35.
116. Fontenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22(3):329-41.
117. Jacobs JF, Nierkens S, Figdor CG, et al. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 2012;13(1):e32-42.
118. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102(51):18538-43.
119. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115(12):3623-33.
120. Rasku MA, Clem AL, Telang S, et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med. 2008;6:12.
121. Litzinger MT, Fernando R, Curiel TJ, et al. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 2007;110(9):3192-201.
122. Telang S, Rasku MA, Clem AL, et al. Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. BMC Cancer. 2011;11(1):515.
123. Attia P, Maker AV, Haworth LR, et al. Inability of a fusion protein of IL-2 and diphtheria toxin (denileukin diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother. 2005;28(6):582-92.
124. Jacobs JF, Punt CJ, Lesterhuis WJ, et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res. 2010;16(20):5067-78.
125. Jones E, Dahm-Vicker M, Simon AK, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2002;2:1.
126. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292-303.
127. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763-71.
128. Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718-30.
129. Barton GM, Kagan JC. A cell biological view of toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol. 2009;9(8):535-42.
130. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008;27(2):161-7.
131. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152(5):939-47.
132. Adams S, O'Neill DW, Nonaka D, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol. 2008;181(1):776-84.
133. Flaherty TK. Targeting metastatic melanoma. Annu Rev Med. 2012;63:21.1-21.13.
134. Flahert KT, Fisher DE. New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances. Clin Cancer Res. 2011;17(15):4922-8.
135. Flaherty TK, Hodi FS, Bastian BC. Mutation-driven drug development in melanoma. Curr Opin Oncol. 2010;22(3):178-83.
136. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16.
137. Tsao H, Goel V, Wu H, et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 2004;122:337-41.
138. Uribe P, Wistuba II, Gonzalea S. BRAF mutation: a frequent event in benign, atypical and malignant melanocytic lesions of the skin. Am J Dermatopathol. 2003;25(5):365-70.
139. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-19.
140. Ribas AK, Kim KB, Schuchter L, et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib (PLX4032, RG7204) in previously treated patients with BRAFV600E mutation-positive metastatic melanoma [abstract]. J Clin Oncol. 2011;29(Suppl):8509.
141. Zelboraf [package insert]. San Francisco: Genetech USA; 2011.
142. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1858-9.
143. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-65.
144. Hochhaus A. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Ann Hematol. 2004;83(Suppl. 1):S65-6.
145. Beading C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14(21):6821-8.
146. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib responses in patients with metastatic gastrointestinal tumor. J Clin Oncol. 2003;21:4342-9.
147. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;26(12):2046-51.
148. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-34.
149. Smalley KS, Flaherty KT. Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer. 2009;100(3):431-5.
150. Yeh TC, Marsh V, Bennet BA, et al. Biological characterization of AARY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13:1576-83.
151. Friday BB, Yu C, Dy GK, et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res. 2008;68:6145-53.
152. Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK 1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2011;18(2):555-67.
153. von Moos R, Seifert B, Simcock M, et al. First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol. 2011;23(2):531-6.
154. Grignol V, Olencki T, Relekar K, et al. A phase II trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother. 2011;34(6):509-15.
155. Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012;30(1):34-41.
156. Dankort D, Curley DP, Cartlidge RA, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nature Genet. 2008;41:544-52.
157. Malley KS, Contractor R, Nguyen TK, et al. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res. 2008;68(14):5743-52.
158. Prickett TD, Agrawal NS, Wei X, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet. 2009;41(10):1127-32.
159. Van Raamsdonk CD, Berzrokove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457:599-602.
160. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;436:117-22.
161. Wellbroick C, Rana S, Peterson H, et al. Oncogenic BRAD regulates melanoma proliferation through the lineage specific factor MITF. PLoS One. 2008;3:e2734.
162. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973-7.
163. Muthusamy V, Hobbs C, Noguera C, et al. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chrom Cancer. 2006;45:447-54.
164. Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors and induce marked T cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18(5):1386-94.
165. Blank CU, Hooijkaas AI, Haanen JB, et al. Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol Immunother. 2011;60:1359-71.